Wu Tsai Neurosciences Institute
Showing 1-10 of 50 Results
Associate Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology-Adult)On Partial Leave from 09/15/2021 To 03/14/2022
Current Research and Scholarly InterestsPrimary research interests include the nature and treatment of eating disorders
(particularly bulimia nervosa and binge eating disorder), the development and treatment of obesity, and the development and treatment of problematic eating patterns in patients following bariatric surgery.
Assistant Professor (Research) of Psychiatry and Behavioral Sciences (Interdisciplinary Brain Science Research)
Current Research and Scholarly InterestsThe overarching goal of my research is to develop reliable computational methods that will allow for characterizing and modeling temporal dynamics of brain activity, without averaging data in either space or time. I firmly believe that the spatiotemporal richness in brain activity might hold the key to finding the person- and disorder-centric biomarkers. I am currently developing methods to model the temporal dynamics of brain activity in individuals with fragile X syndrome and healthy controls.
Gregory Lee Sahlem
Assistant Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology)
BioDr.Sahlem is an Assistant Professor in the Department of Psychiatry and Behavioral Sciences. He is board-certified in general psychiatry and addictions medicine, as well as fellowship-trained in the research and clinical application of neuromodulation-based treatments including repetitive Transcranial Magnetic Stimulation (rTMS), electroconvulsive therapy (ECT), and vagus nerve stimulation (VNS). He additionally has advanced training in the treatment of mood and sleep disorders. In addition to being an active clinician, Dr.Sahlem is a member of the Stanford Brain Stimulation Lab and directs the Addictions Research Section of the Lab.
Major areas of study for Dr.Sahlem include: The development of rTMS as a focused treatment for addictive disorders; the development of a novel form of ECT theorized to have reduced cognitive side effects, Focal Electrically Administered Seizure Therapy (FEAST), and; the further development of rTMS for the treatment of mood disorders.
Professor of Materials Science and Engineering
Current Research and Scholarly InterestsNovel materials and processing techniques for large-area and flexible electronic/photonic devices. Polymeric materials for electronics, bioelectronics, and biosensors. Electrochemical devices for neuromorphic computing. Defects and structure/property studies of polymeric semiconductors, nano-structured and amorphous materials in thin films. Advanced characterization techniques for soft matter.
Associate Professor of Biomedical Data Science and of Biochemistry
Current Research and Scholarly InterestsCircular RNA regulation and function; computational and experimental approaches
Peter L. Santa Maria, MD, PhD
Associate Professor of Otolaryngology - Head & Neck Surgery (OHNS)
Current Research and Scholarly InterestsWe study chronic suppurative otitis media, a chronic biofilm infection of the middle ear predominantly involving pseudomonas and staph aureus. We are investigating mechanisms of sensory hearing loss, host microbe interactions and trialling novel therapeutics.
Our work in tympanic membrane regeneration has entered clinical trials.
Novel treatments for wound healing in intra oral wounds with potential applications to prevent post tonsillectomy wound healing and oral mucositis.
John A. and Cynthia Fry Gunn Professor and Professor of Neurology and of Neurosurgery
Current Research and Scholarly InterestsNeuron death, stress, gene therapy
Assistant Professor of Pathology
Current Research and Scholarly InterestsOur lab works at the interface of immunology, cancer biology, and genomics to study cellular and molecular mechanisms of the immune response to cancer. In particular, we are leveraging high-throughput genomic technologies to understand the dynamics of the tumor-specific T cell response to cancer antigens and immunotherapies (checkpoint blockade, CAR-T cells, and others). We are also interested in understanding the impact of immuno-editing on the heterogeneity and clonal evolution of cancer.
We previously developed genome sequencing technologies that enable epigenetic studies in primary human immune cells from patients: 1) 3D enhancer-promoter interaction profiling (Nat Genet, 2017), 2) paired epigenome and T cell receptor (TCR) profiling in single cells (Nat Med, 2018), 3) paired epigenome and CRISPR profiling in single cells (Cell, 2019), and high-throughput single-cell ATAC-seq in droplets (Nature Biotech, 2019). We used these tools to study fundamental principles of the T cell response to cancer immunotherapy (PD-1 blockade) directly in cancer patient samples (Nature Biotech, 2019; Nat Med, 2019).